Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24028
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHobart, Jeremy-
dc.contributor.authorZiemssen, T.-
dc.contributor.authorFEYS, Peter-
dc.contributor.authorLinnebank, M.-
dc.contributor.authorGoodman, A.-
dc.contributor.authorFarrell, R.-
dc.contributor.authorEnglishby, V.-
dc.contributor.authorMcNeill, M.-
dc.contributor.authorChang, I.-
dc.contributor.authorMehta, L.-
dc.contributor.authorElkins, J.-
dc.date.accessioned2017-07-19T15:11:59Z-
dc.date.available2017-07-19T15:11:59Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22, p. 833-834 (Art N° 254)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24028-
dc.description.sponsorshipBiogen-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleSustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage834-
dc.identifier.spage833-
dc.identifier.volume22-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Hobart, J.] Plymouth Univ, Peninsula Sch Med, Plymouth Hosp NHS Trust, Plymouth, Devon, England. [Hobart, J.] Plymouth Univ, Peninsula Sch Dent, Plymouth Hosp NHS Trust, Plymouth, Devon, England. [Ziemssen, T.] Univ Clin Dresden, Dresden, Germany. [Feys, P.] Univ Hasselt, Diepenbeek, Belgium. [Linnebank, M.] Univ Zurich Hosp, Zurich, Switzerland. [Goodman, A.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Farrell, R.] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, London, England. [Englishby, V.; McNeill, M.] Biogen, Maidenhead, Berks, England. [Chang, I.; Mehta, L.; Elkins, J.] Biogen, Cambridge, MA USA.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnr254-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.isi000383267203260-
dc.identifier.urlhttps://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/147081/jeremy.hobart.sustained.clinically.meaningful.improvements.in.walking.ability.html?f=m3-
item.contributorHobart, Jeremy-
item.contributorZiemssen, T.-
item.contributorFEYS, Peter-
item.contributorLinnebank, M.-
item.contributorGoodman, A.-
item.contributorFarrell, R.-
item.contributorEnglishby, V.-
item.contributorMcNeill, M.-
item.contributorChang, I.-
item.contributorMehta, L.-
item.contributorElkins, J.-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationHobart, Jeremy; Ziemssen, T.; FEYS, Peter; Linnebank, M.; Goodman, A.; Farrell, R.; Englishby, V.; McNeill, M.; Chang, I.; Mehta, L. & Elkins, J. (2016) Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study.. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 833-834 (Art N° 254).-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Abstract.pdfPeer-reviewed author version252.66 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Jul 23, 2024

Page view(s)

20
checked on Sep 7, 2022

Download(s)

4
checked on Sep 7, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.